All trials View full record on ClinicalTrials.gov
NCT07214727PHASE1RECRUITING
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
✨ Plain-English version on the way · ~2 days
We're still translating this one. In a couple of days, you'll see what this trial actually tests — and whether it matters for APOE4 carriers like you. For now, here's the sponsor's own description:
The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administrationRead full record on ClinicalTrials.gov
Eligibility check — Phoenix members
Phoenix members see for THIS trial:
- APOE genotype match
- Cognitive status fits inclusion
- Specific exclusions flagged
- Distance to nearest site
Sites
11 locations
Start
2025-10-15
Interventions tested
- DRUGALN-5288
- DRUGPlacebo